The role of sodium glucose co-transporter inhibitors in heart failure prevention

Vishnu Garla; Angela Subauste; Javed Butler; Lillian F Lien

doi:10.1016/j.jdiacomp.2020.107811

The role of sodium glucose co-transporter inhibitors in heart failure prevention

J Diabetes Complications. 2021 Mar;35(3):107811. doi: 10.1016/j.jdiacomp.2020.107811. Epub 2020 Nov 26.

Authors

Vishnu Garla¹, Angela Subauste², Javed Butler³, Lillian F Lien²

Affiliations

¹ Department of Medicine, University of Mississippi Medical Center, Jackson, USA; Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Mississippi Medical Center, Jackson, USA; Mississippi Center for Clinical and Translational Research, University of Mississippi Medical Center, Jackson, USA. Electronic address: vgarla@umc.edu.
² Department of Medicine, University of Mississippi Medical Center, Jackson, USA; Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Mississippi Medical Center, Jackson, USA.
³ Department of Medicine, University of Mississippi Medical Center, Jackson, USA.

PMID: 33280983
DOI: 10.1016/j.jdiacomp.2020.107811

Abstract

The worldwide prevalences of diabetes mellitus (DM) and of heart failure (HF) have collectively been on the rise. HF accounts for a large portion of the cardiovascular mortality and morbidity associated with DM. DM increases the risk of developing heart failure by promoting atherosclerosis and exerting direct deleterious effects on the myocardium. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are agents approved for the treatment of DM; they exert their anti-hyperglycemic effects by blocking renal reabsorption of glucose and inducing glycosuria. SGLT-2 inhibitors have consistently decreased the hospitalization rate of HF and cardiovascular mortality in several clinical trials. SGLT-2 inhibitors also possess anti-inflammatory, anti-fibrotic, and antihypertensive in addition to beneficial effects on the myocardial metabolism, which may account for their heart failure benefits. However, further research still needs to be done to evaluate the use of SGLT-2 inhibitors in non-diabetic patients and their efficacy in preventing or treating different heart failure phenotypes.

Keywords: Diabetes mellitus; Heart failure; Sodium glucose co-transporter-2 inhibitors.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucose
Heart Failure* / complications
Heart Failure* / epidemiology
Heart Failure* / prevention & control
Humans
Hypoglycemic Agents / therapeutic use
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Symporters*

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Symporters
Sodium
Glucose